Cryo-Cell International (CCEL) 10-Q2024 Q1 Quarterly report

Filed: 15 Apr 24, 5:10pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: adipose, agreed, answering, BMAC, budget, conducive, corticosteroid, counterclaim, dropping, flexibility, fourth, Fraction, group, identification, injection, lender, Master, month, newly, OA, outlined, paragraph, post, precision, protocol, quarterly, recoverability, RMAT, scheduled, shown, spinning, spinoff, spun, stream, subsidiary, SVF, undertaken, unilateral, Vascular

Removed: controlling, CP, executed, extended, extinguishment, judgement, LIBOR, Minnesota, neurological, pandemic, pediatric, promissory, readout, receipt, recording, responded, Restated, senior, TCB, therewith, weighted

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

CCEL similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Cryo-Cell International, Inc. (the “Company”) on Form 10-Q for the quarter ended February 29, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David Portnoy, Co-Chief Executive Officer of the Company, I, Mark Portnoy, Co-Chief Executive Officer of the Company, and I, Jill M. Taymans, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


	/s/ David Portnoy
	David Portnoy
	Co-Chief Executive Officer

	April 15, 2024

	/s/ Mark Portnoy
	Mark Portnoy
	Co-Chief Executive Officer

	April 15, 2024

	/s/ Jill M. Taymans
	Jill M. Taymans
	Vice President, Finance (Chief Financial Officer)

	April 15, 2024

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.